KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Common Equity (2016 - 2025)

Historic Common Equity for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $31.3 billion.

  • Regeneron Pharmaceuticals' Common Equity rose 648.4% to $31.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.3 billion, marking a year-over-year increase of 648.4%. This contributed to the annual value of $31.3 billion for FY2025, which is 648.4% up from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Common Equity stood at $31.3 billion, which was up 648.4% from $31.0 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Common Equity ranged from a high of $31.3 billion in Q4 2025 and a low of $12.0 billion during Q1 2021
  • Over the past 5 years, Regeneron Pharmaceuticals' median Common Equity value was $24.5 billion (recorded in 2023), while the average stood at $24.1 billion.
  • The largest annual percentage gain for Regeneron Pharmaceuticals' Common Equity in the last 5 years was 7044.1% (2021), contrasted with its biggest fall of 128.57% (2021).
  • Regeneron Pharmaceuticals' Common Equity (Quarter) stood at $18.8 billion in 2021, then grew by 20.75% to $22.7 billion in 2022, then grew by 14.6% to $26.0 billion in 2023, then rose by 13.02% to $29.4 billion in 2024, then grew by 6.48% to $31.3 billion in 2025.
  • Its Common Equity was $31.3 billion in Q4 2025, compared to $31.0 billion in Q3 2025 and $29.9 billion in Q2 2025.